Last reviewed · How we verify
SMC with SP+AQ
SMC with SP+AQ is a seasonal malaria chemoprevention regimen combining sulfadoxine-pyrimethamine and amodiaquine to prevent malaria infection in children during high-transmission seasons.
SMC with SP+AQ is a seasonal malaria chemoprevention regimen combining sulfadoxine-pyrimethamine and amodiaquine to prevent malaria infection in children during high-transmission seasons. Used for Seasonal malaria chemoprevention in children aged 3-59 months in sub-Saharan Africa during high-transmission seasons.
At a glance
| Generic name | SMC with SP+AQ |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Antimalarial combination therapy |
| Target | Plasmodium falciparum dihydrofolate reductase, dihydropteroate synthase, and quinoline-sensitive targets |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
This combination therapy uses two antimalarial agents with complementary mechanisms: sulfadoxine-pyrimethamine inhibits dihydrofolate reductase and dihydropteroate synthase in the malaria parasite, while amodiaquine acts as a quinoline antimalarial. Administered as intermittent preventive treatment during peak malaria transmission seasons, the regimen provides sustained protection by maintaining therapeutic drug levels that suppress parasitemia and prevent clinical malaria episodes in vulnerable pediatric populations.
Approved indications
- Seasonal malaria chemoprevention in children aged 3-59 months in sub-Saharan Africa during high-transmission seasons
Common side effects
- Gastrointestinal disturbances
- Pruritus
- Rash
- Headache
Key clinical trials
- MDA and Targeted Control Against Plasmodium Carriage in the Sahel (NA)
- Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC) (NA)
- Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal (PHASE4)
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (PHASE3)
- Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique (PHASE4)
- Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control (NA)
- Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SMC with SP+AQ CI brief — competitive landscape report
- SMC with SP+AQ updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI